Coalition's gameplan for digital regs

Share this article:
Mark Bard
Mark Bard

Weary of FDA foot-dragging on digital and social media guidance for pharmas, a group of 60-some industry digerati recently put together guidelines of their own.

The Digital Health Coalition (DHC) said its seven “Guiding Principles and Best Practices for Companies and Users,” while not official company policies, are a consensus of the industry's top digital marketers.

Questions of control over content—and when pharmas are responsible for correcting misinformation they find online—were the thorniest, said founder Mark Bard, and will be explored further by a working group.

For now, the DHC presented the issue in principle No. 2, stating that regulated healthcare companies “are not responsible for user-generated content online that they do not control.” Companies are deemed to “control” health and medical content if they own that content and have material editorial authority over it or if  they paid for the content and have material editorial authority over it.

As regards obligations to correct misinformation, the DHC's principles say they “should endeavor to make reasonable efforts to correct misinformation.”

The seven principles, said DHC's Joe Farris, “are a starting point. We don't view them as the holy grail of guidance.” The group hopes they will inform FDA thinking on the topic.

“It's very helpful to regulators to communicate what consensus thinking around topics is today,” says Bard.

The principles and best practices address these points:

1) Social media participation

2) When companies are deemed to “control” health and medical content

3) The responsibility companies have to report adverse events

4) When employees of regulated healthcare companies should disclose their company relationship

5) Ensuring timely responses to questions on sites they control, especially in crisis and emergency situations

6) Making reasonable efforts to correct misinformation

7) Tasking employee(s) with the role of “patient liaison,” focused on representing the best interests of the patient online
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?